Xeris Pharmaceuticals is a specialty pharmaceutical company leveraging novel non-aqueous formulation platforms, XeriSol™ and XeriJect™, to develop and commercialize highly-concentrated (up to 400mg/mL or more), smaller volume, ready-to-use subcutaneous and intramuscular injectables. As the first proof of concept, we have developed the first and only ready-to-use, room-temperature stable liquid glucagon formulation (Gvoke HypoPen(TM)) for the treatment of severe hypoglycemia. The FDA PDUFA date is June 10 2019, with the commercial launch to follow in H2 2019. Clinical development in other novel indications is ongoing. Xeris is also applying our formulation platforms to other drugs to address existing solubility and stability challenges. XeriSol is best suited for peptides and small molecules; XeriJect is best suited for large molecule (proteins, mAbs and vaccines). Xeris strongly believes that our best-in-class formulation platforms have the potential to transform patient care.